Request to Join
has invited you to join this group
Professor Patrick CY Woo obtained his medical degree in The University of Hong Kong in 1991. He joined the Department of Microbiology of The University of Hong Kong in 1997, and became Professor of Microbiology in 2006 and Head of Department in 2011. Professor Woo is consistently among the top 1% researchers and has established himself as a leader in the field of emerging infectious diseases, novel microbe discovery and microbial genomics. He has published more than 400 journal articles, and his work has been published in New England Journal of Medicine, Lancet, PNAS, Cell Host & Microbe, British Medical Journal, PLoS Pathogens, PLoS Genetics, etc.
Tim is an Academic Clinical Lecturer at the University of Oxford, UK, and part of the Modernising Medical Microbiology consortium (http://modmedmicro.nsms.ox.ac.uk). He first read Politics, Philosophy and Economics at the University of Oxford before qualifying in Clinical Medicine from the University of London and training to be an infectious diseases physician and microbiologist in Oxford. He gained his DPhil from the University of Oxford, focussing on the application of whole genome sequencing technology to the control and treatment of Mycobacterium tuberculosis infection. His current interests include the translation of this technology to the diagnostic realm to help improve drug susceptibility predictions as well as our understanding of transmission networks. His work has contributed towards the decision to roll-out whole genome sequencing technology in M. tuberculosis reference laboratories in England. He has received awards for this work, including from the British Infection Association and from the European Society for Clinical Microbiology and Infectious Diseases.
Marian is a scientist in the Health Systems Research Unit of the South African Medical Research Council. She worked at different levels within the health systems of South Africa for many years before moving into research. These included work at a community level training and managing a community health worker and rehabilitation worker programme; work as a district health manager; and as a district facilitator assisting districts most in need of improving their primary health care services, including the TB programme. She then moved into research focusing on health systems research through the lens of TB, drug resistant TB and HIV. Although she is now in a research post, she continues to work closely with different levels of the department of health assisting with policy development, evaluation and service implementation.
Dr. Dick Menzies received his medical training at McGill University, Montreal and specialty training in Internal Medicine at the Medical College of Pennsylvania in Philadelphia, USA. After a 2 ½ year stint in Lesotho, Africa, he received further training in Respiratory Medicine and a Masters degree in Epidemiology & Biostatistics at McGill University. Dr. Menzies has served as Medical Director at the Montreal Chest Institute for a total of 10 years ending in 2002 and as Director of the Respiratory Epidemiology Unit at McGill University for 7 years, and as Director of the Respiratory Division for 9 years. Dr. Menzies has a long history of involvement in tuberculosis care and research, beginning with his years in Lesotho, where tuberculosis is highly endemic. Since his return to Montreal he has developed a tuberculosis research programme of clinical and epidemiologic studies linked with a large multi-disciplinary clinical service at the Montreal Chest Institute. This service collaborates closely with the Public Health Unit of Montreal and Immigration Canada for screening of newly arrived foreign-born and others at high risk for tuberculosis. He developed and lead collaborative groups in nosocomial transmission of TB, MDR-TB treatment, and large scale randomized trials in 9 countries. Dr. Menzies has also been involved as a consultant to National TB Programs in the Dominican Republic, Guyana and Ecuador, and was on sabbatical at WHO in 2014-15 where he helped develop the Global Action Framework for TB Research. He has published over 280 peer-reviewed papers and more than 30 book chapters based on the results of his research.
Jason Andrews is an Assistant Professor in the Division of Infectious Diseases and Geographic Medicine at Stanford University and a practicing infectious diseases physician. His research focuses on evaluating transmission dynamics and strategies for control of tuberculosis and tropical diseases.
Jason Farley, PhD, MPH, ANP-BC, FAAN, AACRN: Dr. Jason Farley is an Associate Professor at Johns Hopkins University School of Nursing and a nurse practitioner in the Division of Infectious Diseases within The Johns Hopkins AIDS Service. Dr. Farley's research seeks to optimize the prevention and management of HIV infection with a particular emphasis on drug resistant Tuberculosis among persons with HIV in international settings. His work is supported through NIH, CDC-SA, HRSA, Global Fund for AIDS, TB and Malaria as well as many others. In the US, he is a leader in Pre-Exposure Prophylaxis (PrEP) working with the Baltimore City Health Department to implement a city-wide initiative to increase access and retention of PrEP services in men who have sex with men. Dr. Farley is the Director of the Johns Hopkins AETC for Nurse Practitioner Education. He is MidAtlantic AETC Regional Director for Johns Hopkins. Dr. Farley leads The Johns Hopkins HIV Prevention Trials Network (HPTN) within the School of Medicine and the Founder of the REACH Initiative of Johns Hopkins University School of Nursing. He is currently the President of the Association of Nurses in AIDS Care (ANAC), the world's largest HIV focused nursing organization.
Keertan Dheda is Professor of Respiratory Medicine, and Head of the Division of Pulmonology, Department of Medicine, at the University of Cape Town, where he also serves as the Director of the Interventional Pulmonology Program. He graduated with a medical degree from the University of the Witwatersrand in 1992 and completed his PhD in TB immunology in 2005 at UCL in London. His research work focuses on (i) the epidemiology, diagnosis, transmission, and treatment of MDR & XDR-TB and (ii) studying the immunopathogenesis of TB using human lung cells, tissues and challenge models. He has published over 200 peer-reviewed papers and had made seminal contributions to the field drug-resistant TB. He was the recipient of the 2010 International Union Against Tuberculosis and Lung Disease Scientific Award recognising his significant contributions in this area. He has been profiled in The Lancet (see http://www.thelancet.com/journals/lancet/issue/vol383no9915/PIIS0140-6736(14)X6068-X ), and is regularly quoted and consulted by national and international news agencies and the media. He serves on the editorial board of several journals including PLoS One, American Journal of Respiratory and Critical Medicine, Lancet Respiratory Diseases and Nature Scientific Reports, amongst others. He holds 3 patents related to new TB diagnostic or infection control technologies. He serves on several national and international academic and advisory bodies.
Dr. Karen Jacobson is an Assistant Professor of Medicine in the Section of Infectious Diseases, Boston University School of Medicine, with a secondary appointment in the Department of Epidemiology, Boston University School of Public Health. Dr. Jacobson’s research focuses on the epidemiology of tuberculosis and drug resistant tuberculosis, including identification of social, biological, and economic determinants of and risk factors for drug resistance and approaches for improving TB outcomes in resource-limited settings. Dr. Jacobson has established a highly productive collaboration with researchers in South Africa, investigating the drivers of drug resistance in the Western Cape Province of South Africa and working to identify potentially modifiable factors. She is also studying the impact of problem alcohol use on tuberculosis treatment response, aiming to clarify the causal mechanisms including impact on pharmacokinetics of the drugs.
Edward Nardell, MD, is an associate physician in the Division of Pulmonary and Critical Care Medicine at Brigham & Woman’s Hospital, and associate professor at Harvard Medical School (Medicine), and at Harvard School of Public Health (Immunology and Infectious Disease; Environmental Health). His clinical service at BWH is on the pulmonary consult service and in the mycobacterial disease clinic. He has more than 35 years experience diagnosing and treating tuberculosis and other mycobacterial infections, drug resistant tuberculosis in particular. For more than 12 consecutive years he has been listed among Boston Magazine’s Best Doctors under pulmonary medicine. Before coming to BWH he was for 24 years chief of pulmonary medicine at The Cambridge Health Alliance, another Harvard teaching hospital. He served as TB Control Officer for Massachusetts Department of Public Health for 18 years, overseeing DPH TB clinics around the state. He has served as president of the Massachusetts Thoracic Society and the International Union Against Tuberculosis and Lung Disease (North American Region). His research interests include tuberculosis transmission and its control, focusing on building design and engineering. He also studies inhaled delivery of drugs for TB and other mycobacterial infections. He co- moderates a BWH Global Health Delivery interactive website on TB infection control: www.GHDonline.org.